Literature DB >> 6223989

Phosphate-activated glutaminase in relation to Huntington's disease and agonal state.

J Butterworth, C M Yates, J Simpson.   

Abstract

Involvement of phosphate-activated glutaminase in Huntington's disease and agonal state was investigated in caudate nucleus and frontal cortex from postmortem brains. In Huntington's disease the activities of phosphate-activated glutaminase, glutamic acid decarboxylase, succinic dehydrogenase, choline acetyltransferase, and acetylcholinesterase were significantly reduced in the caudate nucleus, but not in the frontal cortex. The activity of phosphate-activated glutaminase, and to a lesser extent of glutamic acid decarboxylase, was reduced in cases of terminal illness, as compared with cases of sudden death. Succinic dehydrogenase and choline acetyltransferase were reduced only in the few cases of prolonged and severe terminal illness. Enzyme activities of the caudate nucleus were more affected by agonal state than were those of frontal cortex. Results indicate that phosphate-activated glutaminase could be a useful marker of neuronal damage due to agonal state, and that phosphate-activated glutaminase and succinic dehydrogenase are reduced in Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223989     DOI: 10.1111/j.1471-4159.1983.tb04761.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.

Authors:  Nima N Naseri; Hui Xu; Joseph Bonica; Jean Paul G Vonsattel; Etty P Cortes; Larry C Park; Jamshid Arjomand; Gary E Gibson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

3.  Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitors.

Authors:  Hejun Lu; Richard B Silverman
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

Review 4.  Towards an Understanding of Energy Impairment in Huntington's Disease Brain.

Authors:  Janet M Dubinsky
Journal:  J Huntingtons Dis       Date:  2017

5.  Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways.

Authors:  Jennifer Fazzari; Katja Linher-Melville; Gurmit Singh
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.